Antibody Discovery Market By Methods (Phage Display, Hybridoma, Others), By Antibody Type (Humanized Antibody, Human Antibody, Chimeric Antibody, Murine Antibody), By End Users (Pharmaceutical and Biotechnology industry, Research laboratory, Academic laboratory): Global Opportunity Analysis and Industry Forecast, 2023-2032
The antibody discovery market was valued at $6.9 billion in 2022, and is estimated to reach $17.2 billion by 2032, growing at a CAGR of 9.6% from 2023 to 2032.Antibody discovery is defined as a process of identifying novel therapeutic antibodies to treat a wide range of diseases such as autoimmune diseases, cancer, human immunodeficiency virus, and hereditary diseases. The antibody discovery process is different from the traditional discovery of small molecules, as it requires the engineering of antibodies and development of hybridomas to recognize a specific target protein. The antibody discovery includes various steps such as target assessment, followed by hit generation and lead optimization, through a variety of molecular engineering and synthetic biology methods.
The antibody discovery market is driven by the increase in demand for antibody in various R&D activities and advancement in technology in the antibody discovery process. Antibody is one of the most commonly used candidate for development of drugs. It is used to detect, isolate, and quantify proteins, as well as to identify and study the molecular and cellular pathways that are involved in a variety of diseases. They are also used to develop vaccines, therapeutics, and diagnostic tests. In addition, antibodies are used in research centers to study the structure and function of proteins, drug development, and other biomedical applications. For instance, in November 2022, Ablexis, LLC, a biopharmaceutical company, announced the licensing of AlivaMab mouse technology for antibody drug discovery. The technology increases the process of antibody drug engineering. The novel strain of AlivaMab XKL mice aims to enhance the epitope and molecular diversity of immune response during antibody drug discovery.
The increase in adoption of key strategies such as product launch and product expansion drive the growth of the market. For instance, in November 2022, Ablexis, LLC and AlivaMab Discovery Services, announced the expansion of platform for antibody drug discovery and engineering process. Moreover, in December 2021, OpenEye Scientific and Specifica, Inc, announced the launch of orion antibody discovery suite. It is a next generation sequencing software, which helps bioinformaticians and antibody manufacturing engineer at biotechnology and pharmaceutical companies to advance antibody discovery by identifying a wide range of antibody set with advanced properties for downstream therapeutic development. Thus, increase in product launch propels the growth of the market.
In addition, rise in prevalence of cancer & other chronic diseases, surge in adoption of antibody in the treatment of several diseases including inflammatory, cancer, & autoimmune diseases, and increase in investment in R&D activities in pharmaceutical and biotechnology industry propel the growth of the market. The most common approach for antibody discovery is the use of phage display method. In addition, antibodies can be used to detect the presence of cancer cells in the body, aiding in the early diagnosis of the disease. For instance, in December 2021, BioGenex, an automated staining provider for cancer diagnosis, announced the launch of three novel antibody for diagnosis of cancer. According to the Worldwide Cancer Data, in 2020, around 18.1 million people across the globe were diagnosed with cancer. Thus, the increase in demand for antibody in diagnosis of cancer foster the need for antibody development.
In addition, increase in geriatric population fosters the demand for therapeutic antibody, which drives the growth of the antibody market. Geriatric population is more prone to chronic diseases that augments the need for customized and tailored antibody, which boost the demand for antibody discovery services. Furthermore, the increase in need for antibody discovery for the development of novel therapeutics and vaccine boost the growth of the market.
Moreover, rise in prevalence of neurogenerative diseases, such as alzheimer, parkinsons, and huntington, boost the growth of the antibody discovery market. Furthermore, rise in number of government fundings for R&D activities further boost the market growth. For instance, in March 2023, Antiverse Ltd, a biotechnology company, announced that it has raised $3 million in funding, to enable in-house development of the antibodies.
However, a factor that hinders the market growth is high cost of antibody discovery process. On the other hand, increase in the number of R&D activities for novel antibody manufacturing and increase in number of key players who provide antibody discovery services are expected to create immense opportunities for antibody discovery market during the forecast period.
The antibody discovery market is segmented on the basis of method, antibody type, end user, and region. On the basis of method, the market is classified into phage display, hybridoma, and others. On the basis of antibody type, the market is categorized into humanized antibody, human antibody, chimeric antibody, and murine antibody.
On the basis of end user, the market is fragmented into pharmaceutical & biotechnology industry, research laboratory, and academic laboratory.
Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global antibody discovery market are Genscript Technology, Danaher Corporation, Twist Bioscience HQ, Sartorius AG, Charles River Laboratories, Eurofins Discovery, Fairjourney Biologics SA, Biocytogen, Creative Biolab, and Evotec. Key players operating in the market have adopted product launch and others as their key strategies to expand their market share.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody discovery market analysis from 2022 to 2032 to identify the prevailing antibody discovery market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antibody discovery market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antibody discovery market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Methods
Phage Display
Hybridoma
Others
By Antibody Type
Humanized Antibody
Human Antibody
Chimeric Antibody
Murine Antibody
By End Users
Pharmaceutical and Biotechnology industry
Research laboratory
Academic laboratory
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Biocytogen
Charles River Laboratories
Creative Biolabs
Danaher Corporation
Eurofins Scientific
Evotec
Fairjourney Biologics S.A
Genscript Technology Corporation
Sartorius AG
Twist Bioscience
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increasing investment in R&D activities of antibody discovery
- 3.4.1.2. Surge in prevalence of infectious and chronic disease
- 3.4.1.3. Growth in awareness among individuals regarding early diagnosis detection and personalized medicine
- 3.4.2. Restraints
- 3.4.2.1. High cost of antibody discovery process
- 3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: ANTIBODY DISCOVERY MARKET, BY METHODS
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Phage Display
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Hybridoma
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- CHAPTER 5: ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Humanized Antibody
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Human Antibody
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Chimeric Antibody
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Murine Antibody
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- CHAPTER 6: ANTIBODY DISCOVERY MARKET, BY END USERS
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Pharmaceutical and Biotechnology industry
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Research laboratory
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Academic laboratory
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: ANTIBODY DISCOVERY MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Methods
- 7.2.3. Market size and forecast, by Antibody Type
- 7.2.4. Market size and forecast, by End Users
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Methods
- 7.2.5.1.3. Market size and forecast, by Antibody Type
- 7.2.5.1.4. Market size and forecast, by End Users
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Methods
- 7.2.5.2.3. Market size and forecast, by Antibody Type
- 7.2.5.2.4. Market size and forecast, by End Users
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Methods
- 7.2.5.3.3. Market size and forecast, by Antibody Type
- 7.2.5.3.4. Market size and forecast, by End Users
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Methods
- 7.3.3. Market size and forecast, by Antibody Type
- 7.3.4. Market size and forecast, by End Users
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Methods
- 7.3.5.1.3. Market size and forecast, by Antibody Type
- 7.3.5.1.4. Market size and forecast, by End Users
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Methods
- 7.3.5.2.3. Market size and forecast, by Antibody Type
- 7.3.5.2.4. Market size and forecast, by End Users
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Methods
- 7.3.5.3.3. Market size and forecast, by Antibody Type
- 7.3.5.3.4. Market size and forecast, by End Users
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Methods
- 7.3.5.4.3. Market size and forecast, by Antibody Type
- 7.3.5.4.4. Market size and forecast, by End Users
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Methods
- 7.3.5.5.3. Market size and forecast, by Antibody Type
- 7.3.5.5.4. Market size and forecast, by End Users
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Methods
- 7.3.5.6.3. Market size and forecast, by Antibody Type
- 7.3.5.6.4. Market size and forecast, by End Users
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Methods
- 7.4.3. Market size and forecast, by Antibody Type
- 7.4.4. Market size and forecast, by End Users
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Methods
- 7.4.5.1.3. Market size and forecast, by Antibody Type
- 7.4.5.1.4. Market size and forecast, by End Users
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Methods
- 7.4.5.2.3. Market size and forecast, by Antibody Type
- 7.4.5.2.4. Market size and forecast, by End Users
- 7.4.5.3. Australia
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Methods
- 7.4.5.3.3. Market size and forecast, by Antibody Type
- 7.4.5.3.4. Market size and forecast, by End Users
- 7.4.5.4. India
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Methods
- 7.4.5.4.3. Market size and forecast, by Antibody Type
- 7.4.5.4.4. Market size and forecast, by End Users
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Methods
- 7.4.5.5.3. Market size and forecast, by Antibody Type
- 7.4.5.5.4. Market size and forecast, by End Users
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Methods
- 7.4.5.6.3. Market size and forecast, by Antibody Type
- 7.4.5.6.4. Market size and forecast, by End Users
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Methods
- 7.5.3. Market size and forecast, by Antibody Type
- 7.5.4. Market size and forecast, by End Users
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Methods
- 7.5.5.1.3. Market size and forecast, by Antibody Type
- 7.5.5.1.4. Market size and forecast, by End Users
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Methods
- 7.5.5.2.3. Market size and forecast, by Antibody Type
- 7.5.5.2.4. Market size and forecast, by End Users
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Methods
- 7.5.5.3.3. Market size and forecast, by Antibody Type
- 7.5.5.3.4. Market size and forecast, by End Users
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Methods
- 7.5.5.4.3. Market size and forecast, by Antibody Type
- 7.5.5.4.4. Market size and forecast, by End Users
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Fairjourney Biologics S.A
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Key strategic moves and developments
- 9.2. Biocytogen
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Key strategic moves and developments
- 9.3. Genscript Technology Corporation
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Danaher Corporation
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.5. Creative Biolabs
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.6. Twist Bioscience
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Evotec
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Sartorius AG
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Charles River Laboratories
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Eurofins Scientific
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 02. ANTIBODY DISCOVERY MARKET FOR PHAGE DISPLAY, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. ANTIBODY DISCOVERY MARKET FOR HYBRIDOMA, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. ANTIBODY DISCOVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. GLOBAL ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 06. ANTIBODY DISCOVERY MARKET FOR HUMANIZED ANTIBODY, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. ANTIBODY DISCOVERY MARKET FOR HUMAN ANTIBODY, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. ANTIBODY DISCOVERY MARKET FOR CHIMERIC ANTIBODY, BY REGION, 2022-2032 ($MILLION)
- TABLE 09. ANTIBODY DISCOVERY MARKET FOR MURINE ANTIBODY, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. GLOBAL ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 11. ANTIBODY DISCOVERY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. ANTIBODY DISCOVERY MARKET FOR RESEARCH LABORATORY, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. ANTIBODY DISCOVERY MARKET FOR ACADEMIC LABORATORY, BY REGION, 2022-2032 ($MILLION)
- TABLE 14. ANTIBODY DISCOVERY MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 16. NORTH AMERICA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 17. NORTH AMERICA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 18. NORTH AMERICA ANTIBODY DISCOVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 19. U.S. ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 20. U.S. ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 21. U.S. ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 22. CANADA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 23. CANADA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 24. CANADA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 25. MEXICO ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 26. MEXICO ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 27. MEXICO ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 28. EUROPE ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 29. EUROPE ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 30. EUROPE ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 31. EUROPE ANTIBODY DISCOVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 32. GERMANY ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 33. GERMANY ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 34. GERMANY ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 35. FRANCE ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 36. FRANCE ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 37. FRANCE ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 38. UK ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 39. UK ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 40. UK ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 41. ITALY ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 42. ITALY ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 43. ITALY ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 44. SPAIN ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 45. SPAIN ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 46. SPAIN ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 47. REST OF EUROPE ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 48. REST OF EUROPE ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 49. REST OF EUROPE ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 51. ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 52. ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 53. ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 54. JAPAN ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 55. JAPAN ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 56. JAPAN ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 57. CHINA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 58. CHINA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 59. CHINA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 60. AUSTRALIA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 61. AUSTRALIA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 62. AUSTRALIA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 63. INDIA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 64. INDIA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 65. INDIA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 66. SOUTH KOREA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 67. SOUTH KOREA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 68. SOUTH KOREA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 72. LAMEA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 73. LAMEA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 74. LAMEA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 75. LAMEA ANTIBODY DISCOVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 76. BRAZIL ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 77. BRAZIL ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 78. BRAZIL ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 79. SAUDI ARABIA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 80. SAUDI ARABIA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 81. SAUDI ARABIA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 82. SOUTH AFRICA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 83. SOUTH AFRICA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 84. SOUTH AFRICA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 85. REST OF LAMEA ANTIBODY DISCOVERY MARKET, BY METHODS, 2022-2032 ($MILLION)
- TABLE 86. REST OF LAMEA ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022-2032 ($MILLION)
- TABLE 87. REST OF LAMEA ANTIBODY DISCOVERY MARKET, BY END USERS, 2022-2032 ($MILLION)
- TABLE 88. FAIRJOURNEY BIOLOGICS S.A: KEY EXECUTIVES
- TABLE 89. FAIRJOURNEY BIOLOGICS S.A: COMPANY SNAPSHOT
- TABLE 90. FAIRJOURNEY BIOLOGICS S.A: SERVICE SEGMENTS
- TABLE 91. FAIRJOURNEY BIOLOGICS S.A: PRODUCT PORTFOLIO
- TABLE 92. FAIRJOURNEY BIOLOGICS S.A: KEY STRATERGIES
- TABLE 93. BIOCYTOGEN: KEY EXECUTIVES
- TABLE 94. BIOCYTOGEN: COMPANY SNAPSHOT
- TABLE 95. BIOCYTOGEN: SERVICE SEGMENTS
- TABLE 96. BIOCYTOGEN: PRODUCT PORTFOLIO
- TABLE 97. BIOCYTOGEN: KEY STRATERGIES
- TABLE 98. GENSCRIPT TECHNOLOGY CORPORATION: KEY EXECUTIVES
- TABLE 99. GENSCRIPT TECHNOLOGY CORPORATION: COMPANY SNAPSHOT
- TABLE 100. GENSCRIPT TECHNOLOGY CORPORATION: PRODUCT SEGMENTS
- TABLE 101. GENSCRIPT TECHNOLOGY CORPORATION: SERVICE SEGMENTS
- TABLE 102. GENSCRIPT TECHNOLOGY CORPORATION: PRODUCT PORTFOLIO
- TABLE 103. DANAHER CORPORATION: KEY EXECUTIVES
- TABLE 104. DANAHER CORPORATION: COMPANY SNAPSHOT
- TABLE 105. DANAHER CORPORATION: PRODUCT SEGMENTS
- TABLE 106. DANAHER CORPORATION: PRODUCT PORTFOLIO
- TABLE 107. CREATIVE BIOLABS: KEY EXECUTIVES
- TABLE 108. CREATIVE BIOLABS: COMPANY SNAPSHOT
- TABLE 109. CREATIVE BIOLABS: SERVICE SEGMENTS
- TABLE 110. CREATIVE BIOLABS: PRODUCT PORTFOLIO
- TABLE 111. TWIST BIOSCIENCE: KEY EXECUTIVES
- TABLE 112. TWIST BIOSCIENCE: COMPANY SNAPSHOT
- TABLE 113. TWIST BIOSCIENCE: PRODUCT SEGMENTS
- TABLE 114. TWIST BIOSCIENCE: SERVICE SEGMENTS
- TABLE 115. TWIST BIOSCIENCE: PRODUCT PORTFOLIO
- TABLE 116. EVOTEC: KEY EXECUTIVES
- TABLE 117. EVOTEC: COMPANY SNAPSHOT
- TABLE 118. EVOTEC: SERVICE SEGMENTS
- TABLE 119. EVOTEC: PRODUCT PORTFOLIO
- TABLE 120. SARTORIUS AG: KEY EXECUTIVES
- TABLE 121. SARTORIUS AG: COMPANY SNAPSHOT
- TABLE 122. SARTORIUS AG: PRODUCT SEGMENTS
- TABLE 123. SARTORIUS AG: PRODUCT PORTFOLIO
- TABLE 124. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
- TABLE 125. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
- TABLE 126. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
- TABLE 127. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
- TABLE 128. EUROFINS SCIENTIFIC: KEY EXECUTIVES
- TABLE 129. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
- TABLE 130. EUROFINS SCIENTIFIC: SERVICE SEGMENTS
- TABLE 131. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
- TABLE 132. EUROFINS SCIENTIFIC: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. ANTIBODY DISCOVERY MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF ANTIBODY DISCOVERY MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN ANTIBODY DISCOVERY MARKET (2023-2032)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALANTIBODY DISCOVERY MARKET
- FIGURE 10. ANTIBODY DISCOVERY MARKET, BY METHODS, 2022(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR PHAGE DISPLAY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR HYBRIDOMA, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE, 2022(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR HUMANIZED ANTIBODY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR HUMAN ANTIBODY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR CHIMERIC ANTIBODY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR MURINE ANTIBODY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. ANTIBODY DISCOVERY MARKET, BY END USERS, 2022(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR RESEARCH LABORATORY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ANTIBODY DISCOVERY MARKET FOR ACADEMIC LABORATORY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 23. ANTIBODY DISCOVERY MARKET BY REGION, 2022
- FIGURE 24. U.S. ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 25. CANADA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 26. MEXICO ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 27. GERMANY ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 28. FRANCE ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 29. UK ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 30. ITALY ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 31. SPAIN ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 32. REST OF EUROPE ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 33. JAPAN ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 34. CHINA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 35. AUSTRALIA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 36. INDIA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 37. SOUTH KOREA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 38. REST OF ASIA-PACIFIC ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 39. BRAZIL ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 40. SAUDI ARABIA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 41. SOUTH AFRICA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 42. REST OF LAMEA ANTIBODY DISCOVERY MARKET, 2022-2032 ($MILLION)
- FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 47. COMPETITIVE DASHBOARD
- FIGURE 48. COMPETITIVE HEATMAP: ANTIBODY DISCOVERY MARKET
- FIGURE 49. TOP PLAYER POSITIONING, 2022
- FIGURE 50. GENSCRIPT TECHNOLOGY CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 51. GENSCRIPT TECHNOLOGY CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 52. GENSCRIPT TECHNOLOGY CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 53. DANAHER CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 54. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 55. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 56. TWIST BIOSCIENCE: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 57. TWIST BIOSCIENCE: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 58. EVOTEC: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 59. EVOTEC: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 60. EVOTEC: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 61. SARTORIUS AG: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 62. SARTORIUS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 63. SARTORIUS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 64. CHARLES RIVER LABORATORIES: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 65. CHARLES RIVER LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 66. CHARLES RIVER LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 67. EUROFINS SCIENTIFIC: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 68. EUROFINS SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2021 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook